Chemomab Therapeutics Ltd
Research Chemomab Therapeutics Ltd (CMMB) on Bullrun: market cap USD 16.56M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCMMB
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 16.56M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 1.77M
Valuation Snapshot
latest market cap is USD 16.56M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 9.00M | -USD 11.13M | n/a | 0.02 | USD 7.56M | USD 0 | USD 12.33M |
| FY2024 | USD 0 | -USD 13.95M | -USD 15.39M | n/a | 0.04 | USD 6.07M | USD 324.00K | USD 13.54M |
| FY2023 | USD 0 | -USD 24.22M | -USD 23.61M | n/a | 0.1 | USD 9.29M | USD 392.00K | USD 17.00M |
| FY2022 | n/a | -USD 27.65M | -USD 20.44M | n/a | 0.12 | USD 13.52M | USD 214.00K | USD 36.22M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 16.56M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 11.87M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 34.13M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 5.74M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 36.88M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 78.69M | n/a | n/a | n/a |
About Chemomab Therapeutics Ltd
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Chemomab Therapeutics Ltd's market cap?
Chemomab Therapeutics Ltd's market capitalization is USD 16.56M.
What does Chemomab Therapeutics Ltd do?
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.